Adaptive Biotechnologies Corporation - Common Stock (ADPT)
9.5200
+0.2100 (2.26%)
NASDAQ · Last Trade: Jun 1st, 11:41 PM EDT
Detailed Quote
Previous Close
9.310
Open
9.190
Bid
9.380
Ask
9.620
Day's Range
9.070 - 9.610
52 Week Range
2.990 - 10.28
Volume
1,759,862
Market Cap
1.37B
PE Ratio (TTM)
-10.02
EPS (TTM)
-1.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,576,797
Chart
About Adaptive Biotechnologies Corporation - Common Stock (ADPT)
Adaptive Biotechnologies is a biotechnology company that focuses on harnessing the power of the immune system for disease detection and treatment. The company specializes in developing advanced diagnostic tests that analyze the DNA and RNA of immune cells to identify specific immune responses related to various diseases, including cancer and autoimmune disorders. By leveraging large-scale sequencing technology and sophisticated bioinformatics, Adaptive aims to provide physicians with critical insights that can help guide personalized treatment options and improve patient outcomes. Through its innovative platform, the company seeks to transform how diseases are diagnosed and treated, making significant contributions to the field of precision medicine. Read More
Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL.
ADAPTIVE BIOTECHNOLOGIES (ADPT) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a candidate for growth investors. The stock scores a perfect 10 on technical health but may need consolidation before an optimal entry.
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025.
SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024.
